Iran Press/Asia: Chinese authorities have granted the first invention patent to a domestically developed COVID-19 vaccine candidate, which experts said demonstrates the vaccine's originality and creativity and would enhance the international market's trust in Chinese-developed COVID-19 vaccines.
The vaccine, a recombinant adenovirus vaccine named Ad5-nCoV, is co-developed by Chinese biopharmaceutical firm CanSino Biologics Inc., one of the vaccine candidate's co-developers, and a team led by Chinese military infectious disease expert Chen Wei.
According to a document published on China's National Intellectual Property Administration website, the vaccine can be mass-produced in a short time in the event of an outbreak.
The grant of the patent further confirmed the vaccine's efficacy and safety and convincingly demonstrated the ownership of its intellectual property rights (IPR), CanSino said in a statement on Sunday.
Meanwhile, Saudi Arabia will soon begin Phase III clinical trials on around 5,000 people for a COVID-19 vaccine developed by China's CanSino Biologics Inc, a Saudi health ministry spokesman said on Aug 10.
Russian President Vladimir Putin on August 11 has announced that the country's Health Ministry has approved the world's first COVID-19 vaccine made by the Russian military.
"The vaccine, developed by Moscow’s Gamaleya Institute, received the green light from the Russian Health Ministry on Tuesday," Vladimir Putin revealed.
Putin added that his daughter has already received the shot.
He expressed hope that Russia would soon start mass production of the COVID-19 vaccine.
205/219
Read More:
Iranian Health Minister: production of COVID-19 vaccine in clinical trials
Iran welcomes Russia's achievement in producing coronavirus vaccine
Corona vaccine protectability unpredictable: Head of Pasteur Institute
